Narrow search
Showing 1 - 10 of 890
Cover Image
The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
Glennie, Judith L.; Torrance, George W.; Baladi, Jean … - In: PharmacoEconomics 15 (1999) 5, pp. 459-468
The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....
Persistent link: https://www.econbiz.de/10005449189
Cover Image
Actual Costs Versus Diagnostic-Related Group Reimbursements for Unstable Angina: An Important Distinction for Effective Disease Management
Brunelli, Claudio; Bezante, Gian Paolo; Pasdera, Alberto; … - In: Disease Management and Health Outcomes 5 (1999) 4, pp. 225-232
regarding diagnostic and therapeutic procedures for these patients compared with the reimbursement rates established by the … to gather all the information necessary to establish whether reimbursement rates are covering real costs and to initiate …
Persistent link: https://www.econbiz.de/10005448793
Cover Image
Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions
Anis, Aslam H.; Rahman, Tuhin; Schechter, Martin T. - In: PharmacoEconomics 13 (1998) 1 Part 2, pp. 119-126
Our objective was to institute a cost-effectiveness-based reimbursement eligibility and coverage scheme for drugs in … are based on a critical evaluation of pharmacoeconomic studies submitted by manufacturers seeking reimbursement … with a similar process, with cost-effectiveness criteria for reimbursement eligibility. However, analysis in that province …
Persistent link: https://www.econbiz.de/10005449089
Cover Image
Managing Pharmaceutical Expenditure while Increasing Access: The Pharmaceutical Management Agency (PHARMAC) Experience
Braae, Richard; McNee, Wayne; Moore, David - In: PharmacoEconomics 16 (1999) 6, pp. 649-660
The role of the Pharmaceutical Management Agency (PHARMAC) is to manage pharmaceutical subsidy expenditure in New Zealand. PHARMAC has adopted a proactive approach. It selects the drugs that are to be subsidised and declines to subsidise others. It has established reference pricing across many...
Persistent link: https://www.econbiz.de/10005449322
Cover Image
Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor?
Sclar, David A.; Robison, Linda M.; Skaer, Tracy L.; … - In: Disease Management and Health Outcomes 5 (1999) 6, pp. 339-347
Objective: The purpose of this study was 3-fold: (i) to determine the distribution of US patients diagnosed with schizophrenia and requiring a hospitalisation in the calendar year 1988 or 1992, by primary payer type (Medicare; Medicaid; or private insurance); (ii) to discern the mean inpatient...
Persistent link: https://www.econbiz.de/10005590212
Cover Image
The Selection of Data Sources For Use in Modelling Studies
Nuijten, Mark J.C. - In: PharmacoEconomics 13 (1998) 3, pp. 305-316
Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of...
Persistent link: https://www.econbiz.de/10005449056
Cover Image
Book Review
Adis International Limited - In: PharmacoEconomics 26 (2008) 12, pp. 1065-1065
DOI: 10.2165/0019053-200826120-00008
Persistent link: https://www.econbiz.de/10005243120
Cover Image
Outcomes, Outcomes Research and Disease Management: A View from the UK
Walley, Tom - In: Disease Management and Health Outcomes 5 (1999) 4, pp. 197-207
The UK National Health Service (NHS) is in the process of further reforms aimed at restoring a national focus to its activities and also at enhancing the quality of the service it provides. Key features are: 1. the formation of primary care groups to replace general practitioner (GP)...
Persistent link: https://www.econbiz.de/10005448825
Cover Image
Patient Compliance and its Impact on Treatment Outcomes
Pizzi, Laura T.; Biskupiak, Joseph E. - In: Disease Management and Health Outcomes 6 (1999) 5, pp. 269-278
Despite an abundance of literature that assesses medication compliance associated with specific diseases, its impact on patient outcomes remains poorly characterised, perhaps due to the complexity associated with its influence and measurement. Much of the previous research includes end-points...
Persistent link: https://www.econbiz.de/10005448888
Cover Image
Enhancing Outcomes Research: The Experience of a Community Pharmacist Research Network
Longe, R. Leon; Taylor, A. Thomas; Wade, William E.; … - In: Disease Management and Health Outcomes 6 (1999) 5, pp. 261-268
The emphasis on healthcare in the US is shifting to the ambulatory environment. To date, few studies have evaluated the effects that community pharmacists have on patient care. In an attempt to address this issue, 4 academicians from a college of pharmacy developed a research network of...
Persistent link: https://www.econbiz.de/10005404631